NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in ...
US drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...
US biotech major Amgen will invest about $200 million this year in its new technology center in southern India.
J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
With only four litigation hires making Am Law’s top 25 for this year, firms appear to be gearing up for the expected ...
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback